A recent study reveals that patients who come off new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.
Findings released in a major medical journal demonstrates that while overweight people can lose a large proportion of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals buying such drugs should be informed of the danger of rapid weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight within about 18 months.
Analyzing Therapies
The study, which examined dozens of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through dieting generally have a more gradual weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Experts believe the mechanism of the jabs explains the heightened rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Issue?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, considering the high risk of weight regain, the therapy might need to be life-long.
This opinion is reinforced by drug manufacturers, who note that the results "emphasize the long-term character of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
Individuals who have come off the medication describe a powerful resurgence of hunger.
"It was like a trigger activating and you're instantly ravenous," said an individual.
This challenge is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment.
Growing Use
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while these medications are potent tools for weight loss, they are not a standalone fix and lasting health benefits relies on ongoing lifestyle changes.
